D
DIREVO Biotech AG
Customized solutions for various industries
About DIREVO Biotech AG
In 2000, a new company, DIREVO Biotech AG, was spun out of the renowned Max Planck Institute in Germany to commercialize the groundbreaking research of its co-founder, Nobel Laureate Manfred Eigen. The company was built on a powerful concept called directed evolution. Its core business was a high-throughput technology platform designed to rapidly discover and optimize proteins and enzymes for both the pharmaceutical and industrial sectors. The playbook was clear: create a factory for better bio-molecules. DIREVO's platform could engineer superior therapeutic proteins for drug development or create more efficient enzymes for industrial processes, partnering with giants like Danisco. This strategy attracted significant investment and positioned the company as a leader in the specialized field of protein engineering. The pivotal moment arrived in September 2008. Bayer HealthCare announced it would acquire DIREVO Biotech in an all-cash deal valued at €210 million. Bayer sought to integrate DIREVO's powerful biopharmaceutical discovery engine to bolster its own pipeline of biological drugs. In a concurrent and strategic move, DIREVO's industrial biotechnology unit was spun off into a separate entity, DIREVO Industrial Biotechnology GmbH, backed by the original investors to continue its work outside of pharma. This allowed the core pharmaceutical technology to be absorbed by a major player while letting the industrial side of the business continue on its own trajectory.
Source: Dealroom company dataNews
Open roles
DIREVO Biotech AG in the Cologne ecosystem
The DIREVO Biotech AG office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Techno Venture Management- MBMulligan BioCapital
Sanders Morris Harris
Danish Venture Capital and Private Equity Association
Series B and later4 investors entered at this stage
NRW.BANK
Danisco A/S
TVM Capital Life Science
Signet Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DIREVO Biotech AG on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DIREVO Biotech AG on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


